- Описание
- Отзывы (0)
- Доставка и оплата
Таблетки От Боли У Женщин Ponstan 500
Сильный болеутоляющий и противовоспалительный препарат для купирования боли у женщин в критические дни — таблетки Postan 500 применяют для устранения боли при дисменорее, при предменструальном синдроме (ПМС) и при сильных приступах головной боли.
Также обезболивающие таблетки Ponstan 500 принимают для облегчения мышечной, ревматической – при артритах, травматической, зубной, послеоперационной и головной боли (мигрень) — препарат Postan 500 дает очень хороший эффект обезболивания длительностью около 8-10 часов.
Способ применения
по 1 таблетке 3 раза в день после еды по мере необходимости
Противопоказания
- язвенная болезнь желудка и двенадцатиперстной кишки
- беременность и лактация
- детский возраст до 5 лет
Объем: 10 шт.
ДОСТАВКА
Все товары отправляются только из Тайланда
Выдача посылки в ближайшем почтовом отделении
Доставку товаров осуществляют почтовые службы Таиланда и Почта России
Срок доставки
Посылки отправляются авиапочтой, срок доставки зависит от региона:
- Центральный, Северо-Западный, Южный, Приволжский, Северо-Кавказский (Москва, Санкт-Петербург, Ростов-на-Дону, Нижний Новгород, Тверь, Сратов, Пятигорск, Анапа) — 7-14 дней
- Уральский, Сибирский (Екатеринбург, Пермь, Красноярск, Новосибирск, Омск, ) — 10-21 день
- Дальневосточный (Владивосток, Южно-Сахалинск, Улан-Удэ) — 14-21 день
ОПЛАТА
Оплата любым удобным способом
Обращаем Ваше внимание, что мы не отправляем заказы наложенным платежом, оплата при получении не возможна!
Отправка происходит только после 100% оплаты заказа!
Оплата через мобильное приложение банка
Вы можете оплатить заказ по номеру карты (Сбер) через мобильное приложение или на сайте банка
Оплата онлайн
Оплата онлайн осуществляется через платежный шлюз Юкасса по защищенному HTTPS протоколу.
Top 20 medicines with the same components:
Top 20 medicines with the same treatments:
Ponstanâ„¢ Forte Tablets 500mg
Yellow film coated tablet, inscribed ‘Ponstan Forte’ on one side.
Mefenamic acid is a non-steroidal anti-inflammatory agent with analgesic properties, and a demonstrable antipyretic effect. It has been shown to inhibit prostaglandin activity.
Indications
1. As an anti-inflammatory analgesic for the symptomatic relief of rheumatoid arthritis (including Still’s Disease), osteoarthritis, and pain including muscular, traumatic and dental pain, headaches of most aetiology, post-operative and post-partum pain.
2. Primary dysmenorrhoea.
3. Menorrhagia due to dysfunctional causes and presence of an IUD when other pelvic pathology has been ruled out.
Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms
For oral administration
Adults
1 tablet (500mg) three times daily.
In menorrhagia to be administered on the first day of excessive bleeding and continued according to the judgement of the physician
In dysmenorrhoea to be administered at the onset of menstrual pain and continued according to the judgement of the physician.
Elderly (over 65 Years)
As for adults.
Whilst no pharmacokinetic or clinical studies specific to the elderly have been undertaken with Ponstan, it has been used at normal dosage in trials which included many elderly patients.
The elderly are at increased risk of the serious consequences of adverse reactions. If an NSAID is considered necessary, the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for GI bleeding during NSAID therapy.
Ponstan should be used with caution in elderly patients suffering from dehydration and renal disease. Non-oliguric renal failure and proctocolitis have been reported mainly in elderly patients who have not discontinued mefenamic Acid after the development of diarrhoea.
Children
It is recommended that children under 12 years of age should be given Mefenamic Acid Suspension (50mg/5ml).
Do not exceed the stated dose.
Ponstan Forte tablets should be taken preferably with or after food.
Hypersensitivity to mefenamic acid or any of the other ingredients.
Inflammatory bowel disease
History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy.
Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).
Severe heart failure, hepatic failure and renal failure.
Because the potential exists for cross-sensitivity to aspirin, ibuprofen, or other non-steroidal anti-inflammatory drugs, mefenamic acid must not be given to patients who have previously shown hypersensitivity reaction (e.g. asthma, bronchospasm, rhinitis, angioedema or urticaria) to these medicines.
During the last trimester of pregnancy.
Treatment of pain after coronary artery bypass graft (CABG) surgery.
).
Patients on prolonged therapy should be kept under regular surveillance with particular attention to liver dysfunction, rash, blood dyscrasias or development of diarrhoea.
Appearance of any of these symptoms should be regarded as an indication to stop therapy immediately.
Use with concomitant NSAIDs including cyclooxygenase 2 specific inhibitors.
Prolonged use of any type of painkiller for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained and treatment should be discontinued. The diagnosis of ‘Medication Overuse Headache’ should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of headache medications.
Precaution should be taken in patients suffering from dehydration and renal disease, particularly the elderly.
Elderly: The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal.
Respiratory disorders: Caution is required if administered to patients suffering from, or with a previous history of, bronchial asthma since NSAIDs have been reported to precipitate bronchospasm in such patients
Cardiovascular, Renal and Hepatic impairment: The administration of an NSAID may cause a dose dependant reduction in prostaglandin formation and precipitate renal failure.).
Cardiovascular and cerebrovascular effects: Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.
Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for mefenamic acid.
Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with mefenamic acid after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).
As NSAIDs can interfere with platelet function, they should be used in caution in patients with intracranial haemorrhage and bleeding diathesis.
Gastrointestinal bleeding, ulceration and perforation: GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious GI events. Smoking and alcohol use are added risk factors.
The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation , and in the elderly. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for patients at risk of GI bleeding such as the elderly, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (see below and 4.5).
Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.
Caution should be advised in patients receiving concomitant medications which could increase the risk of gastrotoxicity or bleeding such as corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as aspirin.
When GI bleeding or ulceration occurs in patients receiving mefenamic acid the treatment should be withdrawn.
SLE and mixed connective tissue disease: In patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders there may be an increased risk of aseptic meningitis.
Skin reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported in association with use of NSAIDs. Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Mefenamic acid should be stopped at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity.
Female fertility: The use of mefenamic acid may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of mefenamic acid should be considered.
In dysmenorrhoea and menorrhagia lack of response should alert the physician to investigate other causes.
Epilepsy: Caution should be exercised when treating patients suffering from epilepsy.
Sunset yellow may cause allergic-type reactions.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
In patients who are known or suspected to be poor CYP2C9 metabolisers based on previous history/experience with other CYP2C9 substrates, mefenamic acid should be administered with caution as they may have abnormally high plasma levels due to reduced metabolic clearance.
Effects on ability to drive and use machines
Undesirable effects such as dizziness, drowsiness, fatigue and visual disturbances are possible after taking NSAIDs. If affected, patients should not drive or operate machinery.
Undesirable effects
The most frequently reported side effects associated with mefenamic acid involve the gastrointestinal tract.
Diarrhoea occasionally occurs following the use of mefenamic acid. Although this may occur soon after starting treatment, it may also occur after several months of continuous use. The diarrhoea has been investigated in some patients who have continued this drug in spite of its continued presence. These patients were found to have associated proctocolitis. If diarrhoea does develop the drug should be withdrawn immediately and this patient should not receive mefenamic acid again.
Frequencies are not known for the following adverse reactions:
Blood and the lymphatic system disorders
Haemolytic anaemia*, anaemia, hypoplasia bone marrow, haematocrit decreased, thrombocytopenic purpura, temporary lowering of the white blood cell count (leukopenia) with a risk of infection, sepsis, and disseminated intravascular coagulation.
Agranulocytosis, aplastic anaemia, eosinophilia, neutropenia, pancytopenia, thrombocytopenia.
*reversible when mefenamic acid is stopped
Immune system disorders
Hypersensitivity reactions have been reported following treatment with NSAIDs. These may consist of (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity comprising asthma, aggravated asthma, bronchospasm, or dyspnoea or (c) assorted skin disorders including rashes of various types, pruritus, urticaria, purpura, angioedema, and more rarely exfoliative or bullous dermatoses (including epidermal necrolysis and erythema multiforme).
Metabolism and nutritional disorders
Glucose intolerance in diabetic patients, hyponatraemia.
Pyschiatric disorders
Confusion, depression, hallucinations, nervousness.
Nervous system disorders
Optic neuritis, headaches, paraesthesia, dizziness, drowsiness, reports of aseptic meningitis (especially in patients with existing auto-immune disorders, such as systemic lupus erythematosus, mixed connective tissue disease), with symptoms such as stiff neck, headache, nausea, vomiting, fever or disorientation.
Blurred vision, convulsions, insomnia.
Eye disorders
Eye irritation, reversible loss of colour vision, visual disturbances.
Ear and labyrinth disorders
Ear pain, tinnitus, vertigo.
Cardiac / Vascular disorders
Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment.
Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke).
Palpitations.
Hypotension.
Respiratory, thoracic and mediastinal disorders
Asthma, dyspnoea.
Gastrointestinal disorders
The most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur. Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn’s disease have been reported following administration. Less frequently, gastritis has been observed.
Elderly or debilitated patients seem to tolerate gastrointestinal ulceration or bleeding less well than other individuals and most spontaneous reports of fatal GI events are in this population.
Anorexia, colitis, enterocolitis, gastric ulceration with or without haemorrhage, pancreatitis, steatorrhea.
Hepato-bilary disorders
Borderline elevations of one or more liver function tests, cholestatic jaundice.
Mild hepatotoxicity, hepatitis, hepatorenal syndrome.
Skin and subcutaneous tissue disorders
Angioedema, laryngeal oedema, erythema multiforme, face oedema, bullous reactions including Lyell’s syndrome (toxic epidermal necrolysis) and Stevens-Johnson syndrome, perspiration, rash, photosensitivity reaction, pruritus and urticaria.
Renal and urinary disorders
Allergic glomerulonephritis, acute interstitial nephritis, dysuria, haematuria, nephrotic syndrome, non-oliguric renal failure (particularly in dehydration), proteinuria, renal failure including renal papillary necrosis.
General disorders
Fatigue, malaise, multi-organ failure, pyrexia.
Investigations
A positive reaction in certain tests for bile in the urine of patients receiving Mefenamic acid has been demonstrated to be due to the presence of the drug and its metabolites and not to the presence of bile.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Overdose
It is important that the recommended dose is not exceeded and the regime adhered to since some reports have involved daily dosages under 3g.
(a) Symptoms
Symptoms include headache, nausea, vomiting epigastric pain, gastrointestinal bleeding, rarely diarrhoea, disorientation, excitation, coma, drowsiness, tinnitus, fainting, occasionally convulsions [Mefenamic acid has a tendency to induce tonic-clonic (grand mal) convulsions in overdose]. In cases of significant poisoning acute renal failure and liver damage are possible.
(b) Therapeutic measure
Patients should be treated symptomatically as required
Within one hour of ingestion of a potentially toxic amount activated charcoal should be considered. Alternatively, in adults gastric lavage should be considered within one hour of ingestion of a potentially life-threatening overdose.
Good urine output should be ensured
Renal and liver function should be closely monitored.
Patients should be observed for at least four hours after ingestion of potentially toxic amounts
Frequent or prolonged convulsions should be treated with intravenous diazepam.
Other measures may be indicated by the patient’s clinical condition.
Haemodialysis is of little value since mefenamic acid and its metabolites are firmly bound to plasma proteins.
Pharmacodynamic properties
ANIMAL MODELS
Mefenamic acid is non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties.
Its anti-inflammatory effect was first established in the UV erythema model of inflammation. Further studies included inhibition of granulation tissue growth into subcutaneous cotton pellets in rats and carrageenin induced rat paw oedema tests.
Antipyretic activity was demonstrated in yeast-induced pyresis in rats. In this model its antipyretic activity was roughly equal to that of phenylbutazone and flufenamic acid, but less than that of indomethacin.
Analgesic activity was demonstrated in tests involving pain sensitivity of rats paws inflamed by brewers yeast. Mefenamic acid was less potent than flufenamic acid in this model.
Prostaglandins are implicated in a number of disease processes including inflammation, modulation of the pain response, dysmenorrhoea, menorrhagia and pyrexia.
In common with most NSAIDs mefenamic acid inhibits the action of prostaglandin synthetase (cyclo oxygenase). This results in a reduction in the rate of prostaglandin synthesis and reduced prostaglandin levels.
The anti-inflammatory activity of NSAIDs in the rat paw oedema test has been correlated with their ability to inhibit prostaglandin synthetase. When mefenamic acid is ranked in both these tests it falls between indomethacin and phenylbutazone and it is probable that inhibition of prostaglandin synthesis contributes to the pharmacological activity and clinical efficacy of mefenamic acid.
There is also considerable evidence that the fenamates inhibit the action of prostaglandins after they have been formed. They therefore both inhibit the synthesis and response to prostaglandins. This double blockade may well be important in their mode of action.
Pharmacokinetic properties
Absorption and Distribution
Mefenamic acid is absorbed from the gastro intestinal tract. Peak levels of 10 mg/l occur two hours after the administration of a 1g oral dose to adults.
Metabolism
Mefenamic acid is predominantly metabolised by cytochrome P450 enzyme CYP2C9 in the liver, first to a 3 hydroxymethyl derivative (metabolite I) and then a 3 carboxyl derivative (metabolite II). Both metabolites undergo secondary conjugation to form glucuronides.
Therefore in patients who are known or suspected to be poor CYP2C9 metabolisers based on previous history/experience with other CYP2C9 substrates, mefenamic acid should be administered with caution as they may have abnormally high plasma levels due to reduced metabolic clearance.
Elimination
Fifty two percent of a dose is recovered from the urine, 6% as mefenamic acid, 25% as metabolite I and 21% as metabolite II. Assay of stools over a 3 day period accounted for 10-20 % of the dose chiefly as unconjugated metabolite II.
The plasma levels of unconjugated mefenamic acid decline with a half life of approximately two hours.
Preclinical safety data
Preclinical safety data does not add anything of further significance to the prescriber.
List of excipients
Lactose, pregelatinised starch, maize starch, povidone, silicon dioxide, talc, magnesium stearate, croscarmellose sodium type A, sodium laurilsulfate, purified water*, Opadry OY-LS-22808 (H.P.M.C.2910 15cP, lactose, polyethylene glycol 4000, vanillin, E104, E110, E171), Opaglos AG7350 (purified water, beeswax white, carnauba wax yellow, polysorbate 20, sorbic acid).
*not detectable
Shelf life
36 months for amber polystyrene bottle
48 months for blister and HDPE DUMA and polypropylene container
Special precautions for storage
Store below 30°C.
Nature and contents of container
a) Aluminium foil/pvc blister pack in cardboard carton. Pack sizes: 100
b) HDPE DUMA and polypropylene container. Pack sizes: 100 and 500
c) Amber polystyrene bottle with a high density polyethene anti-arthritic closure. Pack sizes: 6, 12, 84, 100 and 500.
Special precautions for disposal and other handling
Not applicable
Marketing authorisation holder
Chemidex Pharma Limited
Chemidex House
Egham Business Village
Crabtree Road
Egham
Surrey TW20 8RB
United Kingdom
Marketing authorisation number(s)
PL 17736/0007
Date of first authorisation/renewal of the authorisation
10/10/2005
Date of revision of the text
12/07/2015
Ponstan Forte price
We have no data on the cost of the drug.
However, we will provide data for each active ingredient
The approximate cost of Mefenamic Acid 250 mg per unit in online pharmacies is from 0.48$ to 0.95$, per package is from 48$ to 95$.
The approximate cost of Mefenamic Acid 500 mg per unit in online pharmacies is from 0.58$ to 0.58$, per package is from 58$ to 58$.
References:
- https://www.drugs.com/search.php?searchterm=ponstan-forte
- https://pubmed.ncbi.nlm.nih.gov/?term=ponstan-forte
Available in countries
Find in a country:
Описание
Обезболивающее Ponstan 500 мг 10 таблеток / 10 tabs Эффективный препарат, помогающий забыть о боли!Тайский препарат высшего качества, который пользуется огромной популярностью! Ponstan может быть использован для облегчения боли при ревматоидном артрите, болезни Стилла, остеоартрите, бродикардии, мышечной, головной, зубной боли, боли, вызванной травмами, послеродовой и послеоперационной болей, а также при первичной дисменорее, болезненных месячных.В состав входит мефенаминовая кислота, сильный анальгетик, жаропонижающий и противовоспалительный нестероидный агент, который также обладает способностью снижать активность накопленного простагландина (является одной из причин боли во время менструации). Таблетки помогают быстро справиться с дискомфортом, болью различного характера, имеют продолжительное действие. Такой надежный помощник, как Ponstan, сохранит Ваши планы, хорошее настроение и здоровье!Применение: взрослым: по 1 таблетке 3 раза в день во время или после приема пищи(максимальная дозировка). Для облегчения боли во время месячных рекомендуется начать прием заранее (за 1-2 дня). Для минимизации возможных побочных эффектов повышайте дозировку препарат постепенно. Внимание! Перед приемом обязательно изучите противопоказания к приему препаратов на основе мефенаминовой кислоты. Желательна консультация с врачом. Людям старше 65 лет принимать препарат с особой осторожностью. Не превышть указанной дозировки!
Patient Information leaflet
PACKAGE LEAFLET: INFORMATION FOR THE USER
PONSTAN FORTE 500 MG FILM-COATED TABLETS
mefenamic acid
IR1-2/L/x/1
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not pass it on to
others. It may
harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor or pharmacist. This
includes any
possible side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. WHAT PONSTAN FORTE IS AND WHAT IT IS USED FOR
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PONSTAN FORTE
3. HOW TO TAKE PONSTAN FORTE
4. POSSIBLE SIDE EFFECTS
5. HOW TO STORE PONSTAN FORTE
6. CONTENTS OF THE PACK AND OTHER INFORMATION
1.
WHAT PONSTAN FORTE IS AND WHAT IT IS USED FORE
d for
Ponstan Forte tablets contain mefenamic acid which is a non-steroidal
anti-inflammatory
drug (NSAID).
They can help to relieve:
symptoms of inflammation, such as redness and swelling
pain and discomfort caused by arthritis, muscular or rheumatic
disorders
headache or toothache
pain after operations, trauma
childbirth pain
painful or heavy periods
symptoms of premenstrual syndrome (PMS).
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE PONSTAN FORTE
2. BEFORE YOU TAKE
DO NOT TAKE PONSTAN FORTE:
if you are allergic to mefenamic acid, to any other anti-inflammatory
medicines (such
as aspirin, ibuprofen, celecoxib), or any of the other ingredients of
this medicine
(listed in section 6)
if you have, or have ever had, stomach or intestinal conditions such
as peptic ulcer,
bleeding in the stomach, intestines or bowel, or severe gastritis,
especially if you
have taken NSAIDs before
if you have an inflammatory bowel disease (e.g. ulcerative colitis,
Crohn's disease)
if you have severe heart, liver or kidney problems
if you ar
Read the complete document
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Ponstan Forte 500 mg Film-coated Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 500 mg mefenamic acid
Excipients with known effect:
Each film-coated tablet contains 22.73 mg lactose monohydrate, 0.067
mg Sunset yellow (E110) and less than 1 mmol
sodium (23 mg)
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Film-coated tablet. (Tablet)
Ovoid tablets with yellow film-coating inscribed ‘PONSTAN FORTE’
on one side.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
1.
As an anti-inflammatory analgesic for symptomatic relief of mild to
moderate pain associated with rheumatic,
muscular or arthritic disorders (including rheumatoid arthritis and
osteoarthritis), trauma, headache, dental pain,
post-operative or post-partum states.
2.
In the management of dysfunctional menorrhagia.
3.
Primary dysmenorrhoea.
4.
Premenstrual syndrome.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Oral.
Undesirable effects may be minimised by using the lowest effective
dose for the shortest duration necessary to control
symptoms_ (see section 4.4, Special warnings and precautions for
use)._
_ADULTS:_
The usual total daily dosage is 1500 mg in divided doses.
_ELDERLY:_
NSAIDs should be used with particular caution in elderly patients who
are more prone to adverse events, especially
with long-term use. Therefore, the risks versus the benefits of
chronic therapy in the elderly should be carefully
considered. The lowest dose compatible with adequate safe clinical
control should be employed_ (see section 4.4,_
_Special warnings and precautions for use)._
Treatment should be reviewed at regular intervals and discontinued if
no benefit is seen or intolerance occurs.
_CHILDREN:_
Not recommended for children under 12 years of age.
Do not exceed the stated dose.
Ponstan should be taken preferably with or after food.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
__
Read the complete document
Ponstan Forte Tablet, Tablets, Film Coated
Ponstan Forte, an anthranilic acid derivative, is a prototypical NSAID. It reversibly inhibits the cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) enzymes, thus resulting in reduced synthesis of prostaglandin precursors. It has analgesic and antipyretic properties with minor anti-inflammatory activity.
Ponstan Forte, an anthranilic acid derivative, is a member of the fenamate group of nonsteroidal anti-inflammatory drugs (NSAIDs). It exhibits anti-inflammatory, analgesic, and antipyretic activities. Similar to other NSAIDs, mefenamic acid inhibits prostaglandin synthetase.
Download Bissoy App to talk Doctor online
Uses
Ponstan Forte is used in mild to moderate pain including headache, dental pain, postoperative and postpartum pain, dysmenorrhoea, menorrhagia, in musculoskeletal and joint disorders such as osteoarthritis and rheumatoid arthritis; and in children with fever and juvenile idiopathic arthritis.
Ponstan Forte is also used to associated treatment for these conditions: Mild pain, Primary Dysmenorrhoea, Gastrointestinal cramps, Moderate Pain
Download Bissoy App to talk Doctor online
How Ponstan Forte works
Ponstan Forte binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. As these receptors have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity, the symptoms of pain are temporarily reduced.
Ponstan Forte
| Trade Name | Ponstan Forte |
| Generic | Mefenamic acid |
| Mefenamic acid Other Names | Acide méfénamique, ácido mefenámico, Acidum mefenamicum, Mefenamic acid, Mefenaminsäure |
| Weight | 500mg, |
| Type | Tablet, Tablets, Film Coated |
| Formula | C15H15NO2 |
| Weight | Average: 241.2851 Monoisotopic: 241.110278729 |
| Protein binding |
90% |
| Groups | Approved |
| Therapeutic Class | Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs) |
| Manufacturer | Pfizer Laboratories Ltd,, Chemidex Pharma Ltd |
| Available Country | Pakistan, United Kingdom, Saudi Arabia, |
| Last Updated: | June 7, 2022 at 8:54 pm |
Structure
Table Of contents
- Ponstan Forte
- Uses
- Dosage
- Side Effect
- Precautions
- Interactions
- Uses during Pregnancy
- Uses during Breastfeeding
- Accute Overdose
- Food Interaction
- Half Life
- Volume of Distribution
- Clearance
- Interaction With other Medicine
- Contradiction
- Storage
Download Bissoy App to talk Doctor online
Dosage
Ponstan Forte dosage
As with other NSAIDs, the lowest dose should be sought for each patient. Therefore, after observing the response to initial therapy with Ponstan Forte, the dose and frequency should be adjusted to suit an individual patient’s needs. Administration is by the oral route, preferably with food.
- Adult: A 500 mg dose should be given to adults up to three times (1.5 g total) per day.
- Infants over 6 months: 25 mg/kg of body weight daily in divided doses for not longer than 7 days.
Download Bissoy App to talk Doctor online
Download Bissoy App to talk Doctor online
Side Effects
In patients taking Ponstan Forte or other NSAIDs, the most frequently reported adverse experiences include : abdominal pain, constipation, diarrhoea, dyspepsia, flatulence, gross bleeding/perforation, heartburn, nausea, GI ulcers, vomiting, abnormal renal function, anaemia, dizziness, oedema, elevated liver enzymes, headache, increased bleeding time, pruritus, rash and tinnitus.
Toxicity
Oral, rat LD50: 740 mg/kg. Symptoms of overdose may include severe stomach pain, coffee ground-like vomit, dark stool, ringing in the ears, change in amount of urine, unusually fast or slow heartbeat, muscle weakness, slow or shallow breathing, confusion, severe headache or loss of consciousness.
Download Bissoy App to talk Doctor online
Precaution
NSAIDs should be prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding. To minimise the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest possible duration. In cases with pre-existing advanced kidney disease, treatment with Ponstan Forte is not recommended.
Interaction
Concomitant use with CYP2C9 isoenzyme inhibitors may alter safety and efficacy of mefenamic acid. May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events with aspirin. May reduce the natriuretic effects of furosemide or thiazide diuretics. Reduced renal lithium clearance and elevated plasma lithium levels. May enhance anticoagulant effect of warfarin.
Food Interaction
- Avoid alcohol.
- Take with food.
Download Bissoy App to talk Doctor online
Volume of Distribution
- 1.06 L/kg [Normal Healthy Adults (18-45 yr)]
Elimination Route
Ponstan Forte is rapidly absorbed after oral administration.
Download Bissoy App to talk Doctor online
Clearance
- Oral cl=21.23 L/hr [Healthy adults (18-45 yrs)]
Elimination Route
The fecal route of elimination accounts for up to 20% of the dose, mainly in the form of unconjugated 3-carboxymefenamic acid.3 The elimination half-life of mefenamic acid is approximately two hours. Ponstan Forte, its metabolites and conjugates are primarily excreted by the kidneys. Both renal and hepatic excretion are significant pathways of elimination.
Pregnancy & Breastfeeding use
Pregnancy: In late pregnancy, as with other NSAIDs, Ponstan Forte should be avoided because it may cause premature closure of the ductus arteriosus. In general there are no adequate and well controlled studies in pregnant women. Ponstan Forte should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. Rated as Pregnancy Category C.
Lactation: Trace amounts of Ponstan Forte may be present in breast milk. Taking into account the importance of the drug to the mother , decision should be made whether to discontinue nursing or to discontinue the drug.
Download Bissoy App to talk Doctor online
Contraindication
Ponstan Forte is contraindicated in patients with known hypersensitivity to Me Ponstan Forte acid. Ponstan Forte should not be given to patients who have experienced asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Rarely fatal, anaphylactic like reactions to NSAIDs have been reported in such patients. Ponstan Forte is contraindicated in patients with active ulceration or chronic inflammation of upper gastrointestinal tract and should not be used in patients with preexisting renal disease.
Acute Overdose
Symptoms: Headache, nausea, vomiting, epigastric pain, GI bleeding. Rarely, diarrhoea, disorientation, excitation, coma, drowsiness, tinnitus, fainting, and occasionally convulsions.
Management: Symptomatic and supportive treatment. In acute overdosage, empty the stomach immediately by inducing emesis or by gastric lavage followed by admin of activated charcoal.
Download Bissoy App to talk Doctor online
Storage Condition
Store between 20-25° C.
Innovators Monograph
You find simplified version here Ponstan Forte
FAQ
What is Ponstan Forte used for?
Ponstan Forte is used short-term to treat mild to moderate pain in adults and children who are at least 14 years old.
How safe is Ponstan Forte?
Ponstan Forte may increase your risk of heart problems, including heart attack, stroke, heart failure, or blood clot. These conditions can be fatal. Your risk may increase if you already have heart disease or have taken the medication for a long period of time or at high doses.
How does Ponstan Forte work?
Ponstan Forte works by stopping the body’s production of a substance that causes pain, fever, and inflammation.
What are the common side effects of Ponstan Forte?
Common side effects of Ponstan Forte are include:
- diarrhea.
- constipation.
- gas or bloating.
- headache.
- dizziness.
- nervousness.
- ringing in the ears
Is Ponstan Forte safe during pregnancy?
Use of Ponstan Forte during pregnancy is not advised unless prescribed by a doctor, especially if you are 30 or more weeks pregnant.
Is Ponstan Forte safe during breastfeeding?
Ponstan Forte passes into breast milk and is not recommended for use while breastfeeding.
Can I drink alcohol with Ponstan Forte?
Do not drink alcohol while taking Ponstan Forte. Alcohol can increase your risk of stomach bleeding caused by Ponstan Forte. Call your doctor at once if you have symptoms of bleeding in your stomach or intestines.
Can I drive after taking Ponstan Forte?
Ponstan Forte Tablets may cause drowsiness, fatigue, dizziness or may affect your vision. If you experience any of these symptoms, you should not drive or operate machinery, or perform any tasks which may require you to be alert.
When should be taken of Ponstan Forte?
Ponstan Forte is usually taken with food every 6 hours as needed for up to 1 week.
Is it safe to take Ponstan Forte?
Ponstan Forte should not be used for longer than 7 days.
How many times can I take Ponstan Forte?
Ponstan Forte take 250 mg every six hours as needed. You shouldn’t take Ponstan Forte for longer than three days.
How long does Ponstan Forte take to work?
If you wait until the symptoms have worsened,Ponstan Forte may not work as well. If you are using Ponstan Forte for painful periods, take your first dose as soon as your period starts or pain begins. Usually, you will only need to take it for the first 2 to 3 days of your period.
How long does it take for Ponstan Forte to kick in?
Ponstan Forte takes between 2 — 4 hours to kick in and start easing your period pain. Each 500mg dose of Ponstan Forte kills pain for up to 8 hours, so you may need to take it two or three times a day for all-day relief.
Can I take Ponstan Forte for a long time?
Ponstan Forte should not be used for longer than 7 days. Follow your doctor’s dosing instructions very carefully. If you use Ponstan Forte long-term, you may need frequent medical tests.Ponstan Forte can cause unusual results with certain medical tests.
Who should not take Ponstan Forte?
Ponstan Forte can increase your risk of fatal heart attack or stroke. Do not use Ponstan Forte just before or after heart bypass surgery .Ponstan Forte may also cause stomach or intestinal bleeding, which can be fatal.
What happens if I miss a dose on Ponstan Forte?
Take Ponstan Forte as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not take two doses at one time.
What happen if I take too much Ponstan Forte?
If you take too much If you take too much Ponstan Forte, you may experience: drowsiness, nausea,vomiting.
When can I stop taking Ponstan Forte?
If you experience any of the following symptoms, stop taking Ponstan Forte and call your doctor: stomach pain, heartburn, vomit that is bloody or looks like coffee grounds, blood in the stool, or black and tarry stools.
Can Ponstan Forte affects my heart ?
Ponstan Forte can increase your risk of fatal heart attack or stroke, especially if you use it long term or take high doses, or if you have heart disease.